NKP-1339
CAS: 197723-00-5
Ref. 3D-XHA72300
| 1mg | Discontinued | ||
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued | ||
| 50mg | Discontinued |
Product Information
NKP-1339 is a drug candidate that has potent anti-cancer activity. It is a small molecule that binds to the grp78 protein, which is involved in cancer cell proliferation and invasion. NKP-1339 inhibits the biological function of grp78 by binding to an intracellular target and blocking energy metabolism. This leads to the death of cancer cells, with no significant effect on healthy cells. NKP-1339 has been tested as a treatment for solid tumors in mice and has shown promising results.
br>br>
NKT Therapeutics Inc., formerly known as Nexus Oncology Inc., was founded in 2003 for the purpose of developing new therapies for cancer patients with limited therapeutic options. The company's initial focus was on treatments for advanced or metastatic cancers where there are few or no approved therapies available.
br>br>
NKP-1339 may offer hope to patients with terminal cancers who have exhausted all other treatment options.
